What it is
Argireline is a trade name for acetyl hexapeptide-8 — six amino acids, also written acetyl hexapeptide-3 in older material. It was designed to resemble the N-terminal end of SNAP-25, one of the proteins that botulinum toxin cleaves in order to stop a nerve signalling a muscle.
That resemblance is the entire pitch. If a peptide occupies the place SNAP-25 would occupy, the reasoning goes, it might interfere with the same assembly — and unlike botulinum toxin it could be spread on the skin rather than injected.
What it is not
It is not a drug. In the United States and the European Union it is a cosmetic ingredient, which means there is no approval to hold, no approved indication, no label, and no regulator who has reviewed whether it works. That is normal for cosmetics and it is not an accusation. It does mean that the evidence question has to be settled from published research, because no agency has done it for you.
The registered trials are about something else
ClinicalTrials.gov holds six studies involving acetyl hexapeptide-8. The two with real clinical design are not cosmetic:
| Study | Sponsor | Condition | Participants | Status |
|---|---|---|---|---|
| NCT00942851 | National Institute of Neurological Disorders and Stroke | Blepharospasm | 24 | Completed |
| NCT01750346 | National Institute of Neurological Disorders and Stroke | Blepharospasm | 8 | Terminated |
Blepharospasm is involuntary forcible closing of the eyelids — a movement disorder, and one of the conditions botulinum toxin injections genuinely treat. It is a sensible place to test a compound claiming to interfere with the same signalling, because the effect would be visible and measurable rather than cosmetic.
The remaining registry entries are what you would expect from the cosmetics side: NCT03878381 is classified Early Phase 1, and NCT06143033 is an eye-serum evaluation with no phase classification at all.
So the strongest clinical work on this compound was done by a US government neurology institute, for a neurological condition, and it does not tell you whether a cream reduces forehead lines.
Two claims, not one
Almost everything written about Argireline runs together two separate propositions:
- The mechanism claim — that the peptide interferes with SNARE-complex assembly the way its design intends. This has support in laboratory systems.
- The delivery claim — that enough of it crosses intact skin, from a cosmetic formulation, to reach a nerve terminal underneath a muscle.
The second is the one that decides whether the first matters, and it is the one that is not settled. A peptide of six amino acids is small by peptide standards, which is the reason for optimism; the skin barrier is a barrier to almost everything, which is the reason for doubt.
How much has been published
44 PubMed records in total, 18 tagged human (E-utilities, 2026-09-08). That is one of the smallest literatures in this library, attached to one of its most widely sold ingredients.
Familiarity is doing a lot of work here. Argireline appears on shelves everywhere and has done for years, and that presence reads as an evidence base it does not have.
Where it stands
Well characterised as a molecule, plausible as a design, and thinly evidenced as a cosmetic. The serious trials studied a different condition; the cosmetic studies are small and early; and the question that would settle it — whether it gets where it would need to go — remains open.
Related entries in this library: GHK-Cu is the other widely sold skin peptide, and its evidence problem is a different one — it has a randomized trial, and that trial was negative on its objective endpoints.
The other widely-sold cosmetic peptide with a trade name standing in for a molecule is Matrixyl, where the brand covers more than one formulation and the literature splits across three different search terms.
Counting those residues is also the quickest sanity check available on a cosmetic peptide's label: the twenty amino acids and what each one weighs turn a published sequence into a molecular weight, and a weight that disagrees with the one on a certificate is worth asking about.
The nearest relative of this compound is the eight-residue peptide sold as SNAP-8, two amino acids longer and marketed as the stronger version. Its evidence problem is sharper again: both of its two published studies test a patch containing several actives at once, so nothing in them can be attributed to the peptide itself.
Last checked
2026-09-08. The ClinicalTrials.gov records for NCT00942851, NCT01750346, NCT03878381 and NCT06143033 were read through the registry API on that date; the PubMed counts were run the same day.